KV Pharmaceutical Acquires Rights to Hologic's Drug for the Prevention of Preterm Birth for $82M

KV Pharmaceutical Acquires Rights to Hologic's Drug for the Prevention of Preterm Birth for $82M

Jan 22 2008

KV Pharmaceutical agreed to pay up to $82 million for U.S. and worldwide rights to Hologic’s Gestiva’s. The drug is pending approval for use in the prevention of preterm birth in certain categories of pregnant women.

The FDA issued an approvable letter in October 2006 and a final approval is anticipated in late 2008, according to the companies. While $7.5 million will be paid upon closing of the agreement, the balance is expected upon final FDA approval and the production of launch quantities of Gestiva. KV expects Gestiva to be additive to its earnings per share in the first 12 months following its launch.

The development of Gestiva was originated by Adeza Biomedical, which was bought by Cytyc. In October Hologic acquired Cytyc.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.